Abstract
The hypoxic injury was induced in rat cerebrocortical slices by the exposure to hypoxia for 45 min in the absence or presence of 3 mM glucose, followed by reoxygenation for 5 h. The injury was more pronounced in the absence of glucose (severe hypoxic injury) than in the presence of glucose (mild hypoxic injury). A novel Na+/Ca2+ channel blocker, NS-7 [4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy) pyrimidine hydrochloride], at 3 to 30 μM inhibited preferentially the severe hypoxic injury, whereas MK-801, ω-conotoxin GVIA (ω-CTX), andNG-nitro-l-arginine methylester suppressed preferentially the mild hypoxic injury. The extracellular cyclic GMP formation, a marker of nitric oxide synthesis, was enhanced during hypoxia, although the extent was greater in the absence of glucose. As observed in the hypoxic injury, NS-7 preferentially inhibited the cyclic GMP formation induced by severe hypoxic insults, whereas MK-801 or ω-CTX reduced it under mild hypoxic condition. When 30 to 50 mM KCl was applied to normoxic slices, a concentration-dependent increase in the extracellular cyclic GMP formation was observed. NS-7 blocked the cyclic GMP formation induced by 50 mM KCl but not by 30 to 40 mM KCl, whereas ω-CTX suppressed only the 30 mM KCl-evoked response. In primary neuronal culture, NS-7 reversed KCl-induced increase in intracellular Ca2+ in which the inhibition was marked when the KCl concentration was increased. These findings suggest that NS-7, unlike other neuroprotective compounds used in this study, is more effective in severe hypoxic injury. The highly voltage-dependent Ca2+channel blockade may contribute to the mode of neuroprotective action of NS-7.
Footnotes
-
Send reprint requests to: Michiko Oka, Research Laboratories, Nippon Shinyaku Co., Ltd., Nishiohji Hachijo Minami-ku, Kyoto 601, Japan. E-mail: m.oka{at}po.nippon-shinyaku.co.jp
- Abbreviations:
- NOS
- nitric-oxide synthase
- LDH
- lactate dehydrogenase
- [Ca2+]i
- intracellular free Ca2+ concentration
- KRB
- Krebs-Ringer- bicarbonate solution
- NO
- nitric oxide
- NS-7
- 4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy) pyrimidine hydrochloride
- ω-CTX
- ω-conotoxin GVIA
- ω-Aga
- ω-agatoxin IVA
- l-NAME
- NG-nitro-l-arginine methylester
- DMEM
- Dulbecco's modified Eagle's minimum essential medium
- BAPTA/AM
- 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid/acetoxymethyl ester
- IBMX
- 3-isobutyl-1-methylxanthine
- NMDA
- N-methyl-d-aspartate
- Received October 12, 1999.
- Accepted January 20, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|